Sodium Valproate

Sodium valproate is an organic compound belonging to the fatty-acid class of anticonvulsants, and it is one of three interchangeable forms of valproate, alongside valproic acid itself and the combined preparation known as valproate semisodium ^[1]. In the body all of these forms deliver the same active valproate ion. It is used chiefly to control epileptic seizures, to treat and prevent episodes of mania in bipolar disorder, and to reduce the frequency of migraine headaches ^[1][2].

The parent molecule, valproic acid, was first prepared in 1882 as a simple organic solvent and had no known biological role for decades. Its anticonvulsant action was discovered by chance in the early 1960s, when French researchers noticed that compounds dissolved in it consistently suppressed seizures in laboratory tests; the solvent, not the dissolved compounds, turned out to be responsible. Valproate has since become one of the most widely used antiseizure medicines in the world.

Because seizure disorders and mood disorders share features such as their episodic course, valproate found a second major role as a mood stabilizer, and it is one of only a handful of anticonvulsants with established efficacy in bipolar disorder ^[2][3]. It is available as tablets, capsules, syrups, slow-release formulations, and an intravenous preparation. The sodium salt and the free acid are often used to describe the same therapy, and a widely marketed version combines the two.

Valproate is a prescription-only medicine and a generic drug, but its use is now tightly regulated because of reproductive safety concerns. It is strongly linked to birth defects and to lasting neurodevelopmental problems in children exposed in the womb, and regulators in the United Kingdom and European Union have restricted its use in people able to become pregnant except under specialist supervision. Regulatory labeling also warns of potentially serious liver toxicity, inflammation of the pancreas, low platelet counts, and a possible increase in suicidal thoughts, so treatment usually includes monitoring.

Valproate is prescription only and needs monitoring. Frequent effects include tremor, weight gain, hair thinning, nausea, and drowsiness. Serious risks are liver toxicity (which can rarely be fatal, mostly in very young children), inflammation of the pancreas, low platelet counts, and a build up of ammonia that can cloud thinking. It is strongly linked to birth defects and lower IQ in babies exposed in the womb, so it is avoided in pregnancy and in people who might conceive unless there is no alternative. It should not be used in people with certain mitochondrial disorders (POLG mutations) or urea cycle disorders.

Valproic acid, the parent of sodium valproate, was first synthesized in 1882 by Beverley Burton and was used for many years merely as an inert organic solvent, with no suspicion of biological activity. Its anticonvulsant properties were discovered by accident in 1962 in France, when Pierre Eymard, working in the laboratory of George Carraz, used valproic acid as a solvent to dissolve other compounds being screened for antiseizure effects and found that the seizures were suppressed regardless of which compound was dissolved, pointing to the solvent itself.

This serendipitous observation led to the recognition of valproate as an antiepileptic, and the sodium salt was introduced clinically in France in 1967 through the company Labaz. Over the following decades sodium valproate became one of the most widely used broad-spectrum anticonvulsants and was also established as a mood stabilizer for bipolar disorder and a preventive treatment for migraine. In later years its use in women of childbearing potential became tightly restricted after strong evidence that exposure during pregnancy causes birth defects and developmental disorders.

Sodium valproate is regarded as one of the workhorses of neurology and psychiatry, valued for its broad effectiveness across many seizure types and for its established role in controlling acute mania in bipolar disorder. Its long clinical history and versatility have kept it in continuous use for over half a century, and network meta-analyses of bipolar mania continue to include it among effective options. Clinicians appreciate that a single drug can serve several different indications, from epilepsy to migraine prevention.

This breadth of activity, spanning several molecular mechanisms, is part of what makes it so useful. It is essential to be candid about its serious risks; valproate carries strong warnings because it can cause major birth defects and impaired development when taken in pregnancy, and it requires monitoring for liver and other effects. Used carefully in appropriate patients, it remains a highly effective and important medicine.